Development and dosimetry of Pb-203 / Pb-212 labeled PSMA ligands – Bringing “the Lead” into PSMA-Targeting Alpha Therapy?
The development of a prostate-specific membrane antigen (PSMA)-ligand for labeling with different radioisotopes of lead and the approximation of the dosimetry of a simulated Pb-212 based alpha-therapy by using its Pb-203 imaging analogue.
KRATOCHWIL Clemens;
DOS SANTOS Jose Carlos;
LEHNERT Wencke;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
HABERKORN Uwe;
KOPKA Klaus;
MIER Walter;
2019-04-11
SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
JRC113789
0029-5566 (online),
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0039-1683594,
https://publications.jrc.ec.europa.eu/repository/handle/JRC113789,
10.1055/s-0039-1683594 (online),
Additional supporting files
| File name | Description | File type | |
|---|
